This is a procurement-oriented overview for distributors, hospitals, and clinics evaluating oncology ablation devices. RFA has an extensive track record in hepatocellular carcinoma (HCC), MWA is frequently applied to liver and lung tumors, and cryoablation is often described for renal cell carcinoma, though indications are always defined by the treating team. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Percutaneous Tumor Ablation
Intracavitary hypothermia describes controlled temperature therapy delivered directly into a body cavity such as the bladder, and is generally positioned as an adjunct intended to enhance the penetration of intravesical chemotherapy. RFA has an extensive track record in hepatocellular carcinoma (HCC), MWA is frequently applied to liver and lung tumors, and cryoablation is often described for renal cell carcinoma, though indications are always defined by the treating team. Because ablation is a local therapy, tumor size, number, location relative to vessels and organs, and overall clinical status all influence whether it is appropriate, as determined by a multidisciplinary clinician team.
Regulatory Status and Manufacturing
INVAMED's ablation portfolio spans several radiofrequency platforms, including the Peta RFA System for soft-tissue, liver, and nerve applications and the multi-application ThermoEdge RFA Platform, as well as the Fusion Intraosseous RFA System for spinal tumors. For intravesical therapy, the HyperTiss Intracavitary Hypothermia Set is positioned for adjunctive use alongside intravesical chemotherapy in bladder cancer. Generator specifications, applicator and antenna options, and compatible accessories are provided in product documentation, and buyers should request the relevant IFU for each variant. Procurement teams should confirm local regulatory registration and approved indications, which vary by market and by device configuration.
Portfolio and Sizing
Within this category, INVAMED lists devices such as HyperTiss Intracavitary Hypothermia Set for Bladder Cancer Treatment, Fusion Intraosseous Radiofrequency Ablation System for Spinal Tumors, Peta Radiofrequency Ablation, ThermoEdge RFA Platform. Size ranges, materials, and configurations are detailed in product documentation and the applicable IFU.
Key Considerations
- Tumor size, number, and proximity to vessels and adjacent organs are central factors in deciding whether ablation is appropriate and which modality to use.
- For lesions near large vessels, the heat-sink effect can influence the completeness of heat-based ablation and is factored into planning.
- Manufacturer descriptions of INVAMED platforms reflect intended design and applications rather than guaranteed individual outcomes.
Frequently Asked Questions
What determines the ablation zone size?
Published sources note that factors such as generator power, applicator design, application time, and local blood flow influence the ablation zone, and settings are selected by the treating physician.
Who decides whether ablation is appropriate?
A qualified clinical team decides based on tumor characteristics and patient factors; this article is educational and not a treatment recommendation.
How is microwave ablation different from radiofrequency ablation?
Both are heat-based, but microwave ablation is often described as heating tissue faster and being less affected by the heat-sink effect near vessels, while RFA has a particularly deep evidence base; the choice is made by the clinician.
About INVAMED
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
Clinical and Technical Context
Manufacturer descriptions of INVAMED platforms reflect intended design and applications rather than guaranteed individual outcomes. Because ablation is a local therapy, tumor size, number, location relative to vessels and organs, and overall clinical status all influence whether it is appropriate, as determined by a multidisciplinary clinician team. MWA is frequently discussed for liver and lung tumors, but suitability, applicator selection, and power protocol are determined case by case by the interventional physician. INVAMED's HyperTiss Intracavitary Hypothermia Set for Bladder Cancer Treatment is an intravesical temperature-therapy set positioned for adjunctive use alongside intravesical chemotherapy for bladder cancer.
Related on INVAMED
- Oncology Ablation — product category
- Fusion Intraosseous Radiofrequency Ablation System for Spinal Tumors — Technical Overview
- Sourcing Oncology Ablation Devices: A Manufacturer and Procurement Guide
- How long is recovery after tumor ablation?
Important Disclaimer
This article is intended for general educational and technical information about medical device technologies. It is not medical advice, a diagnosis, or a treatment recommendation, and it does not replace consultation with a qualified healthcare professional. Any decision about diagnosis or treatment should be made by a licensed clinician based on an individual assessment. INVAMED devices are intended for use by trained healthcare professionals in accordance with the applicable Instructions for Use (IFU) and local regulatory approvals. Product availability and indications vary by country.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.